Vancomycin Capped with Silver Nanoparticles as an Antibacterial Agent against Multi-Drug Resistance Bacteria
Purpose: Many antimicrobial medications are available to combat infections. However, the indiscriminate use of antibiotics has produced antibiotic resistance in the case of many bacterial pathogens. This study focuses on the development of nanoparticles (NPs) that enhance the in vitro antibiotic act...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tabriz University of Medical Sciences
2017-09-01
|
| Series: | Advanced Pharmaceutical Bulletin |
| Subjects: | |
| Online Access: | http://journals.tbzmed.ac.ir/APB/Manuscript/APB-7-479.pdf |
| Summary: | Purpose: Many antimicrobial medications are available to combat
infections. However, the indiscriminate use of antibiotics has produced
antibiotic resistance in the case of many bacterial pathogens. This
study
focuses on the development of nanoparticles (NPs) that enhance the in
vitro
antibiotic activity of vancomycin against multi-drug resistant (MDR)
organisms.
Methods: Spherical shaped thioglycolic acid-stabilized silver
nanoparticles (TGA-AgNPs) were prepared by using a simple chemical
reduction
method. Then, vancomycin was conjugated to the terminal carboxyl of TGA
in the
presence of N-Hydroxysuccinimide (NHS) and
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC).
Afterwards,
the antibacterial activity of these nanoconjugates was examined by using
the
minimum inhibitory concentration (MIC) assay against MDR bacteria.
Results: The rate of vancomycin bound to the AgNPs was 19.6%. The
MIC values of vancomycin (Van)-capped AgNPs against tested pathogens
were in
the range of (3.2, 1.6, 0.8, 0.4, 0.2, 0.1, 0.05, and 0.025 µl/ml). The
MIC was
0.1 µg/ml for VRE, MIC≤0.02 µg/ml for MRSE, and 0.05 µg/ml for S.
aureus.
The MIC corresponded to the MBC for all bacterial species.
Conclusion: This study indicated that some antimicrobial agents like
vancomycin can be conjugated with AgNPs. This can lead to increased
antimicrobial
activity against MDR
microorganisms. |
|---|---|
| ISSN: | 2228-5881 2251-7308 |